Valuation : Mylan N.V.

Market Cap 18.96B 16.33B 15.33B 13.99B 26.29B 1,804B 26.48B 182B 70.68B 915B 71.2B 69.65B 3,030B P/E 2026 *
78.4x
P/E 2027 * 31.1x
Enterprise Value 31.03B 26.72B 25.08B 22.9B 43.02B 2,952B 43.32B 297B 116B 1,497B 117B 114B 4,957B EV / Sales 2026 *
2.1x
EV / Sales 2027 * 2x
Free-Float
91.44%
Yield 2026 *
3.08%
Yield 2027 * 3.16%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 18.96B
+1.22%-4.85%+59.66%+110.70% 1,031B
+0.93%-1.75%+50.71%+67.22% 641B
+1.42%-2.20%+22.66%+75.40% 453B
-1.71%-7.14%+33.40%+33.78% 349B
+5.91%+2.12%+29.07%+46.68% 290B
-0.04%-4.12%+0.95%+11.79% 252B
+0.71%-2.01%+51.04%+68.81% 232B
+0.51%-4.65%-19.61%-54.89% 201B
+1.19%-0.42%+31.44%+93.28% 181B
Average +1.20%-2.98%+28.81%+50.31% 403.31B
Weighted average by Cap. +1.14%-3.97%+38.08%+66.54%

Financials

2026 *2027 *
Net sales 14.78B 12.73B 11.95B 10.91B 20.49B 1,407B 20.64B 142B 55.1B 713B 55.5B 54.3B 2,362B 15.03B 12.94B 12.15B 11.09B 20.84B 1,430B 20.98B 144B 56.02B 725B 56.43B 55.2B 2,401B
Net income -27.26M -23.47M -22.04M -20.12M -37.79M -2.59B -38.06M -261M -102M -1.32B -102M -100M -4.35B 340M 293M 275M 251M 471M 32.34B 475M 3.26B 1.27B 16.4B 1.28B 1.25B 54.3B
Net Debt 12.07B 10.39B 9.75B 8.9B 16.73B 1,148B 16.85B 116B 44.97B 582B 45.3B 44.32B 1,927B 11.08B 9.54B 8.96B 8.18B 15.36B 1,054B 15.47B 106B 41.29B 535B 41.6B 40.69B 1,770B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-